Pfizer Bets Big on China's Obesity Market

Pfizer Inc. has secured exclusive rights to commercialize an obesity therapy in China, signaling an intensified effort in the rapidly expanding weight loss market. The agreement is with the Chinese startup Hangzhou Sciwind Bioscience Co. for their drug ecnoglutide.

This therapy, recently approved in China for diabetes, is currently under review for obesity treatment. The deal carries a potential value of up to $495 million, comprising an upfront payment and milestone-based fees. Pfizer aims to meet the growing demand in China, where obesity impacts 14.1% of the adult population and is a priority under the government's Healthy China initiative.

The drug ecnoglutide operates by mimicking the natural hormone GLP-1, which regulates blood sugar and appetite. Sciwind believes its drug possesses a unique structure that enhances effectiveness and safety compared to other GLP-1 receptor agonists. Late-stage studies indicate ecnoglutide achieves weight loss comparable to Eli Lilly's Zepbound.

Under the terms of the agreement, Sciwind will retain responsibility for the drug's development, manufacturing, and supply. This strategic move could also bolster Pfizer's business in China, which represented 4% of its total revenue as of 2024. The company faces competition from both international and domestic pharmaceutical companies in this market.